logomark
Research

Research

BDR researchers coming from diverse research fields are working together to achieve higher goals.

Seminars & Symposia

Seminars & Symposia

BDR hosts annual symposium and regular seminars inviting international scientists in life science.

Careers & Study

Careers & Study

BDR embraces people from diverse backgrounds, and strives to create an open and supportive setting for research.

Outreach

Outreach

BDR communicates the appeal and significance of our research to society through the use of various media and activities.

News

News

From research, events, people and everything in between, find out what’s going on at RIKEN BDR.

About Us

About Us

Exploring the scientific foundations of life through interdisciplinary approaches to address society’s problems.

Vascular niche and reprogramming for skeletal muscle stem cell
Mar. 22, 2019 16:00 - 17:30

Category

Seminar

Place

Kobe

Venue

DB Bldg. SeminarRoom A7F

Speaker

Atsushi Asakura

Affiliation

Stem Cell Institute, Paul & Sheila Wellstone Muscular Dystrophy Center, Department of Neurology, University of Minnesota Medical School

Muscle satellite cells are a stem cell population responsible for skeletal muscle growth, repair and regeneration. Maintenance of the balance between satellite cell differentiation and self-renewal is required for muscle homeostasis. By utilizing fluorescent reporter mice and muscle tissue clearing to investigate the specific niche for muscle satellite cells in 3 dimensions, we recently reported that the juxtavascular niche of satellite cells for stem cell maintenance via VEGF and Notch pathways (Verma, et al. Cell Stem Cell, 2018). Increased vascular density could induce increased number of satellite cells, which leads to a beneficial effect on muscular dystrophy model mice as a novel therapeutic method of Duchenne muscular dystrophy (DMD). We also identified that ASCL4, a basic-Helix-Loop-Helix transcription factor, possesses an ability to induce myogenic program in pluripotent stem cells, indicating that ASCL4 acts as a myogenic transcription factor during muscle development, and that ASCL4-mediated myogenic conversion of pluripotent stem cells will be a new therapy for DMD.

Host

Fumio Matsuzaki

PAGE
TOP